Journal de recherche sur les tumeurs
Libre accès
ISSN: 2684-1258
ISSN: 2684-1258
Debashis Dutta
Ovarian cancer is heterogeneous, multigenetic and epigenetic abnormalities and lethal among all other gynecological women malignancies amongst women. Moreover, ovarian cancer has a distinct biology and behavior at cellular and molecular level. According to National Cancer Institute’s Surveillance, Epidemiology and End Result Program Report in 2017 the new case of ovarian cancer exacerbated to 22.4% from 11.7% in 2014. The Therapeutics use of cancer therapies has been restricted due to its nonspecific and dose limiting cellular toxicity and development of multidrug resistance. To overcome the restriction various biotechnological therapies and drug delivery system have been described in this review.